FDA Confirms Effexor XR Safe for Generic Copycats to Produce
Published Date: 12/19/2025
Notice
Summary
The FDA has decided that EFFEXOR XR 100 mg capsules were not taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions of this medicine, helping patients access affordable options. No changes in safety rules or costs are expected, so things stay steady for doctors, patients, and pharmacies.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Generics Can Still Be Approved
The FDA found that EFFEXOR XR 100 mg was not withdrawn from sale for reasons of safety or effectiveness. Because of that determination (published December 19, 2025), the Agency will continue to approve abbreviated new drug applications (ANDAs) that refer to this product and will not begin procedures to withdraw approval of existing ANDAs that refer to it.
Labeling Update Guidance Possible
The FDA said EFFEXOR XR 100 mg will remain in the Orange Book 'Discontinued Drug Product List' as discontinued for reasons other than safety or effectiveness. The Agency also stated that if it determines the product's labeling should be revised to meet current standards, it will advise ANDA applicants to submit updated labeling.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in